Edoxaban in Atrial Fibrillation and Venous Thromboembolism—Ten Key Questions and Answers: A Practical Guide

<p><strong>Article full text</strong></p> <p><br> The full text of this article can be found <a href="https://link.springer.com/article/10.1007/s12325-017-0488-9"><b>here</b>.</a><br> <br> <strong>Provide enhanced digital features for this article</strong><br> If you are an author of this publication and would like to provide additional enhanced digital features for your article then please contact <u>[email protected]</u>.<br> <br> The journal offers a range of additional features designed to increase visibility and readership. All features will be thoroughly peer reviewed to ensure the content is of the highest scientific standard and all features are marked as ‘peer reviewed’ to ensure readers are aware that the content has been reviewed to the same level as the articles they are being presented alongside. Moreover, all sponsorship and disclosure information is included to provide complete transparency and adherence to good publication practices. This ensures that however the content is reached the reader has a full understanding of its origin. No fees are charged for hosting additional open access content.<br> <br> Other enhanced features include, but are not limited to:<br> • Slide decks<br> • Videos and animations<br> • Audio abstracts<br> • Audio slides<u></u></p> <p> </p

Freedom from MACCE according to eGFR groups at 12-month follow-up.

<p>Freedom from MACCE according to eGFR groups at 12-month follow-up.</p

Cardiac and antithrombotic medication at discharge.

<p>P-value < 0.05 = *, p value < 0.01 = **, all values are compared with eGFR ≥90mL/min group. Data are reported as number and percentage or mean ± SD; eGFR estimated glomerular filtration rate; VKA, vitamin K antagonist; INR, international normalized ratio; ACEi, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers</p><p>Cardiac and antithrombotic medication at discharge.</p

Freedom from any bleeding event according to eGFR groups at 12-month follow-up.

<p>Freedom from any bleeding event according to eGFR groups at 12-month follow-up.</p

Univariate Cox regression and multivariate nested adjusted models on the relative risk (hazard ratio) of renal impairment on all-cause mortality; major adverse cardiac and cerebrovascular events; and clinically significant bleeding (BARC 2, 3, 5) in patients with AF undergoing PCI as compared with normal eGFR (>90ml/kg/min).

<p>Model A (age (as a continuous variable), sex)</p><p>Model B (age, sex, acute coronary syndrome)</p><p>Model C (age, sex, acute coronary syndrome, previous myocardial infarction, congestive heart failure, center)</p><p>Univariate Cox regression and multivariate nested adjusted models on the relative risk (hazard ratio) of renal impairment on all-cause mortality; major adverse cardiac and cerebrovascular events; and clinically significant bleeding (BARC 2, 3, 5) in patients with AF undergoing PCI as compared with normal eGFR (>90ml/kg/min).</p

Baseline characteristics of the study population.

<p>P-value < 0.05 = *, p value < 0.01 = **, all values are compared with eGFR ≥90 ml/min/1.73 m² group. Data are reported as number and percentage or mean ± SD.; eGFR = estimated glomerular filtration rate; CHA₂ DS₂ VASC = C ongestive heart failure, H ypertension, A ge ≥75 years, D iabetes, prior S troke/transient ischaemic attack/systemic embolism, associated V ascular disease, A ge 65–74 years, and female S ex category; HAS-BLED = Hypertension, Abnormal liver or kidney function, prior Stroke, Bleeding history or predisposition, Labile INR, Elderly, and concomitant Drugs; PCI = percutaneous coronary intervention; CABG = coronary artery bypass graft surgery; TIA = transient ischemic attack.</p><p>Baseline characteristics of the study population.</p

Outcome events at 12-month follow-up.

<p>Data are reported as number of patients (percentage); P-value < 0.05 = *, p value < 0.01 = **, all values are compared with eGFR ≥90mL/min group. eGFR estimated glomerular filtration rate; MACCE, major adverse cardiac/cerebrovascular events; BARC, Bleeding Academic Research Consortium; BARC 1, minimal bleeding complication, BARC 2, requiring nonsurgical, medical intervention by a healthcare professional, leading to hospitalization or increased level of care, or prompting evaluation, but not fit to criteria of BARC>2, Major bleeding complication including fatal bleeding Data are reported as number and percentage or mean ± SD; TIA, transient ischemic attack, AKI = Acute kidney injure with >26.5 μmol/l increase of creatinine.</p><p>Outcome events at 12-month follow-up.</p

Procedural characteristics.

<p>P-value < 0.05 = *, p value < 0.01 = **, all values are compared with eGFR ≥90mL/min group. Data are reported as number and percentage or mean ± SD; eGFR = estimated glomerular filtration rate; PCI = percutaneous coronary intervention; ACS = acute coronary syndrome; STEMI = ST-elevation myocardial infarction; NSTEMI = non ST-elevation myocardial infarction</p><p>Procedural characteristics.</p

Freedom from all-cause mortality according to eGFR groups at 12-month follow-up.

<p>Freedom from all-cause mortality according to eGFR groups at 12-month follow-up.</p